335 related articles for article (PubMed ID: 25655628)
1. Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
Timmermand OV; Tran TA; Strand SE; Axelsson J
J Nucl Med; 2015 Mar; 56(3):444-9. PubMed ID: 25655628
[TBL] [Abstract][Full Text] [Related]
2. Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.
D'Souza JW; Hensley H; Doss M; Beigarten C; Torgov M; Olafsen T; Yu JQ; Robinson MK
J Nucl Med; 2017 Jan; 58(1):175-180. PubMed ID: 27539844
[TBL] [Abstract][Full Text] [Related]
3. Preclinical efficacy of hK2 targeted [
Timmermand OV; Elgqvist J; Beattie KA; Örbom A; Larsson E; Eriksson SE; Thorek DLJ; Beattie BJ; Tran TA; Ulmert D; Strand SE
Theranostics; 2019; 9(8):2129-2142. PubMed ID: 31149033
[TBL] [Abstract][Full Text] [Related]
4. Cerenkov luminescence imaging of medical isotopes.
Ruggiero A; Holland JP; Lewis JS; Grimm J
J Nucl Med; 2010 Jul; 51(7):1123-30. PubMed ID: 20554722
[TBL] [Abstract][Full Text] [Related]
5. Comparative immuno-Cerenkov luminescence and -PET imaging enables detection of PSMA
Maier FC; Wild AM; Kirchen N; Holm F; Fuchs K; Schwenck J; Maurer A; Wiehr S
Appl Radiat Isot; 2019 Jan; 143():149-155. PubMed ID: 30445280
[TBL] [Abstract][Full Text] [Related]
6. Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Lohrmann C; Zhang H; Thorek DL; Desai P; Zanzonico PB; O'Donoghue J; Irwin CP; Reiner T; Grimm J; Weber WA
J Nucl Med; 2015 May; 56(5):805-11. PubMed ID: 25840974
[TBL] [Abstract][Full Text] [Related]
7. Correlation between positron emission tomography and Cerenkov luminescence imaging in vivo and ex vivo using 64Cu-labeled antibodies in a neuroblastoma mouse model.
Maier FC; Schmitt J; Maurer A; Ehrlichmann W; Reischl G; Nikolaou K; Handgretinger R; Pichler BJ; Thaiss WM
Oncotarget; 2016 Oct; 7(41):67403-67411. PubMed ID: 27602580
[TBL] [Abstract][Full Text] [Related]
8. Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.
Timmermand OV; Ulmert D; Evans-Axelsson S; Pettersson K; Bjartell A; Lilja H; Strand SE; Tran TA
EJNMMI Res; 2014 Dec; 4(1):51. PubMed ID: 26116115
[TBL] [Abstract][Full Text] [Related]
9. (68)Ga-labeled 3PRGD2 for dual PET and Cerenkov luminescence imaging of orthotopic human glioblastoma.
Fan D; Zhang X; Zhong L; Liu X; Sun Y; Zhao H; Jia B; Liu Z; Zhu Z; Shi J; Wang F
Bioconjug Chem; 2015 Jun; 26(6):1054-60. PubMed ID: 25853280
[TBL] [Abstract][Full Text] [Related]
10. Multimodal imaging with (18)F-FDG PET and Cerenkov luminescence imaging after MLN4924 treatment in a human lymphoma xenograft model.
Robertson R; Germanos MS; Manfredi MG; Smith PG; Silva MD
J Nucl Med; 2011 Nov; 52(11):1764-9. PubMed ID: 21994410
[TBL] [Abstract][Full Text] [Related]
11. Quantification of Cerenkov Luminescence Imaging (CLI) Comparable With 3-D PET Standard Measurements.
Habte F; Natarajan A; Paik DS; Gambhir SS
Mol Imaging; 2018; 17():1536012118788637. PubMed ID: 30043654
[TBL] [Abstract][Full Text] [Related]
12. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
[TBL] [Abstract][Full Text] [Related]
13. High resolution digital autoradiographic and dosimetric analysis of heterogeneous radioactivity distribution in xenografted prostate tumors.
Timmermand OV; Nilsson J; Strand SE; Elgqvist J
Med Phys; 2016 Dec; 43(12):6632. PubMed ID: 27908170
[TBL] [Abstract][Full Text] [Related]
14. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
[TBL] [Abstract][Full Text] [Related]
15. Proof-of-concept study of monitoring cancer drug therapy with cerenkov luminescence imaging.
Xu Y; Chang E; Liu H; Jiang H; Gambhir SS; Cheng Z
J Nucl Med; 2012 Feb; 53(2):312-317. PubMed ID: 22241909
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of 89Zr-rituximab tracer by Cerenkov luminescence imaging and correlation with PET in a humanized transgenic mouse model to image NHL.
Natarajan A; Habte F; Liu H; Sathirachinda A; Hu X; Cheng Z; Nagamine CM; Gambhir SS
Mol Imaging Biol; 2013 Aug; 15(4):468-75. PubMed ID: 23471750
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
18. β-Radioluminescence Imaging: A Comparative Evaluation with Cerenkov Luminescence Imaging.
King MT; Carpenter CM; Sun C; Ma X; Le QT; Sunwoo JB; Cheng Z; Pratx G; Xing L
J Nucl Med; 2015 Sep; 56(9):1458-64. PubMed ID: 26205301
[TBL] [Abstract][Full Text] [Related]
19. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
20. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
